$644 Million is the total value of BVF INC/IL's 34 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $80,649,000 | -4.1% | 1,591,646 | -24.3% | 12.52% | -12.4% |
| CCXI | Buy | CHEMOCENTRYX INC | $77,205,000 | +32.7% | 8,248,416 | +3.2% | 11.99% | +21.2% |
| ARRY | Buy | ARRAY BIOPHARMA INC | $50,719,000 | +105.3% | 6,059,625 | +119.3% | 7.88% | +87.5% |
| ANAB | Sell | ANAPTYSBIO INC | $39,705,000 | -17.7% | 1,659,200 | -4.6% | 6.17% | -24.9% |
| LOXO | Buy | LOXO ONCOLOGY INC | $37,159,000 | +175.9% | 463,386 | +44.8% | 5.77% | +152.0% |
| GLYC | Buy | GLYCOMIMETICS INC | $33,147,000 | +116.0% | 2,970,182 | +5.1% | 5.15% | +97.2% |
| CTMX | Buy | CYTOMX THERAPEUTICS INC | $31,418,000 | +0.8% | 2,026,998 | +12.3% | 4.88% | -8.0% |
| CTIC | Buy | CTI BIOPHARMA CORP | $28,454,000 | +51.2% | 8,596,357 | +91.9% | 4.42% | +38.1% |
| FWP | FORWARD PHARMA A/Ssponsored adr | $28,215,000 | -5.7% | 1,387,853 | 0.0% | 4.38% | -13.9% | |
| CNCE | Sell | CONCERT PHARMACEUTICALS INC | $25,904,000 | -35.0% | 1,856,895 | -20.5% | 4.02% | -40.7% |
| CYTK | Sell | CYTOKINETICS INC | $24,083,000 | -56.0% | 1,990,321 | -53.3% | 3.74% | -59.8% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $17,669,000 | +254.5% | 3,491,933 | +82.2% | 2.74% | +223.6% |
| ACHN | Buy | ACHILLION PHARMACEUTICALS INC | $16,019,000 | +15.8% | 3,490,077 | +6.2% | 2.49% | +5.7% |
| TOCA | New | TOCAGEN INC | $15,387,000 | – | 1,279,078 | +100.0% | 2.39% | – |
| BLRX | BIOLINERX LTDsponsored adr | $14,875,000 | -11.5% | 17,500,000 | 0.0% | 2.31% | -19.2% | |
| OMED | Buy | ONCOMED PHARMACEUTICALS INC | $14,653,000 | -9.6% | 4,400,289 | +149.9% | 2.28% | -17.5% |
| INFI | INFINITY PHARMACEUTICALS INC | $12,350,000 | -51.4% | 7,866,108 | 0.0% | 1.92% | -55.6% | |
| CASC | CASCADIAN THERAPEUTICS INC | $11,640,000 | -10.3% | 3,133,224 | 0.0% | 1.81% | -18.0% | |
| XENE | Buy | XENON PHARMACEUTICALS INC | $11,084,000 | -6.1% | 3,518,830 | +19.3% | 1.72% | -14.3% |
| XOMA | XOMA CORP DEL | $10,505,000 | -1.7% | 1,502,800 | 0.0% | 1.63% | -10.2% | |
| ARQL | ARQULE INC | $9,176,000 | +17.0% | 7,400,128 | 0.0% | 1.42% | +6.8% | |
| SBPH | New | SPRING BK PHARMACEUTICALS INC | $8,332,000 | – | 615,384 | +100.0% | 1.29% | – |
| RXDX | New | IGNYTA INC | $7,245,000 | – | 700,000 | +100.0% | 1.12% | – |
| NVLS | Buy | NIVALIS THERAPEUTICS INC | $6,374,000 | +17.1% | 2,644,806 | +41.9% | 0.99% | +6.9% |
| GTXI | GTX INC DEL | $5,864,000 | +8.9% | 1,108,433 | 0.0% | 0.91% | -0.5% | |
| OREXIGEN THERAPEUTICS INCnote 2.750% | $5,025,000 | -8.2% | 10,000,000 | 0.0% | 0.78% | -16.2% | ||
| SNSS | Buy | SUNESIS PHARMACEUTICALS INC | $4,781,000 | -24.3% | 1,770,692 | +15.0% | 0.74% | -30.9% |
| ADRO | New | ADURO BIOTECH INC | $3,420,000 | – | 300,000 | +100.0% | 0.53% | – |
| CRVS | New | CORVUS PHARMACEUTICALS INC | $3,318,000 | – | 274,196 | +100.0% | 0.52% | – |
| RGLS | Buy | REGULUS THERAPEUTICS INC | $3,232,000 | +214.4% | 3,278,900 | +426.3% | 0.50% | +186.9% |
| OREXQ | OREXIGEN THERAPEUTICS INC | $2,131,000 | -15.7% | 734,976 | 0.0% | 0.33% | -23.0% | |
| ANTH | New | ANTHERA PHARMACEUTICALS INC | $1,631,000 | – | 1,006,507 | +100.0% | 0.25% | – |
| PTIE | New | PAIN THERAPEUTICS INC | $1,341,000 | – | 325,508 | +100.0% | 0.21% | – |
| FATE | Sell | FATE THERAPEUTICS INC | $1,268,000 | -85.7% | 391,386 | -79.9% | 0.20% | -86.9% |
| PTIE | Exit | PAIN THERAPEUTICS INC | $0 | – | -2,278,552 | -100.0% | -0.35% | – |
| ANTH | Exit | ANTHERA PHARMACEUTICALS INC | $0 | – | -8,052,073 | -100.0% | -0.58% | – |
| IMDZ | Exit | IMMUNE DESIGN CORP | $0 | – | -1,233,976 | -100.0% | -1.43% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.